Cited by 228Advanced Drug Delivery SystemsHIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy

Open access
Kirtane, Ameya R., Abouzid, Omar, Minahan, Daniel, Bensel, Taylor, Hill, Alison L., Selinger, Christian, Bershteyn, Anna, Craig, Morgan +17 more·2018·Nature Communications

Abstract

The efficacy of antiretroviral therapy is significantly compromised by medication non-adherence. Long-acting enteral systems that can ease the burden of daily adherence have not yet been developed. Here we describe an oral dosage form composed of distinct drug–polymer matrices which achieved week-long systemic drug levels of the antiretrovirals dolutegravir, rilpivirine and cabotegravir in a pig. Simulations of viral dynamics and patient adherence patterns indicate that such systems would significantly reduce therapeutic failures and epidemiological modelling suggests that using such an intervention prophylactically could avert hundreds of thousands of new HIV cases. In sum, weekly administration of long-acting antiretrovirals via a novel oral dosage form is a promising intervention to help control the HIV epidemic worldwide.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-017-02294-6

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The authors have developed an orally administered gastric retentive dosage form that can reduce dosing frequency from daily to weekly.

    “we have developed an orally administered gastric retentive dosage form that can reduce dosing frequency from daily to weekly 98 .”

    From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [98]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [61]Andrew Owen et al. Human confirmation of oral dose reduction potential of nanoparticle ARV formulations. Conference on Retroviruses and Opportunistic Infections, abstr. 39 (2017).
  2. [71]Wijting I. et al. Dolutegravir as maintenance monotherapy for HIV-1: a randomized clinical trial. Conference on Retroviruses and Opportunistic Infections, abstr. 451LB (2017).

Cited by

Sorted by citations

Authors
Kirtane, A. R., Abouzid, O., Minahan, D., Bensel, T., Hill, A. L., Selinger, C., Bershteyn, A., Craig, M., Mo, S. S., Mazdiyasni, H., Cleveland, C., Rogner, J., Lee, Y.-A. L., Booth, L., Javid, F., Wu, S. J., Grant, T., Bellinger, A. M., Nikolic, B., Hayward, A., Wood, L., Eckhoff, P. A., Nowak, M. A., Langer, R., & Traverso, G.
Affiliations
  • Koch Institute for Integrative Cancer Research At MIT (US)
  • Harvard University (US)
  • Institute for Disease Modeling (US)
  • Brigham and Women's Hospital (US)
  • Massachusetts Institute of Technology (US)
  • Lyndra Therapeutics (United States) (US)
Corresponding author
Traverso, Giovanni
Venue
Nature Communications
Published
2018-01-09
Volume
9
Issue
1
Pages
2-2
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2781350987
Cited by
227
References
77
Citations by year
2026: 8 · 2025: 19 · 2024: 16 · 2023: 30 · 2022: 23 · 2021: 38 · 2020: 43 · 2019: 28 · 2018: 22
FWCI
13.14
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders
  • Bill and Melinda Gates Foundation (OPP1139937, OPP1139921, OPP1148627)
  • Brigham and Women's Hospital
  • National Institutes of Health (DP5OD019851, 4r37eb000244-34, EB-000244)
  • National Institute of Allergy and Infectious Diseases (R01AI131416, P30AI060354)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB000244, R37-EB000244)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Keywords
HIV antiretroviral therapy, long-acting drug delivery, oral dosage forms, dolutegravir, rilpivirine, cabotegravir, medication adherence, viral dynamics, HIV prevention, prophylaxis, porcine model
MeSH terms
Rilpivirine, Proof of Concept Study, Dolutegravir, Administration, Oral, Animals, Drug Evaluation, Preclinical, Heterocyclic Compounds, 3-Ring, Humans, Models, Theoretical, Oxazines, Patient Compliance, Piperazines, Pyridones, Swine, Drug Delivery Systems, Anti-HIV Agents, Diketopiperazines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review